Details of Drug-Drug Interaction
| Drug General Information (ID: DDI7XH8MOB) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Diphenhydramine | Drug Info | Bretylium | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiallergic Agents | Antiarrhythmic Agents | |||||||
| Structure | |||||||||
| Mechanism of Diphenhydramine-Bretylium Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Diphenhydramine | Bretylium | |||||||
| Mechanism | Prolong QT interval | Prolong QT interval | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | QT interval | ||||||||
| Factor Description | Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Australian authorities recommend avoiding concomitant use of diphenhydramine and class Ia or class III antiarrhythmic agents. Additionally, patients should be counseled to not exceed the recommended dosage and frequency or duration of use of diphenhydramine, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. | ||||||||